Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.200 +0.180 (+17.65%)
Official Closing Price Updated: 8:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,423,763
Open 1.030
Bid (Size) 1.220 (2)
Ask (Size) 1.230 (26)
Prev. Close 1.020
Today's Range 1.029 - 1.310
52wk Range 0.3651 - 1.310
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Lineage Cell Revenue Doubles in Q2
Via The Motley Fool

Performance

YTD
+133.0%
+133.0%
1 Month
+17.6%
+17.6%
3 Month
+159.2%
+159.2%
6 Month
+72.7%
+72.7%
1 Year
+38.9%
+38.9%

More News

Read More
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss
Via Chartmill
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
A Peek at Lineage Cell Therapeutics's Future Earnings
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock
Via Benzinga
Earnings Scheduled For August 12, 2025
Via Benzinga
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Two Biotech Stocks Poised For Big Moves On Monday
Via Benzinga
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook
Via Benzinga
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For May 13, 2025
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Which stocks are moving after the closing bell on Wednesday?
Via Chartmill
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 10, 2025
Via Benzinga

Frequently Asked Questions

Is Lineage Cell Therapeutics, Inc. Common Stock publicly traded?
Yes, Lineage Cell Therapeutics, Inc. Common Stock is publicly traded.
What exchange does Lineage Cell Therapeutics, Inc. Common Stock trade on?
Lineage Cell Therapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock?
The ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock is LCTX on the New York Stock Exchange
What is the current price of Lineage Cell Therapeutics, Inc. Common Stock?
The current price of Lineage Cell Therapeutics, Inc. Common Stock is 1.200
When was Lineage Cell Therapeutics, Inc. Common Stock last traded?
The last trade of Lineage Cell Therapeutics, Inc. Common Stock was at 08/15/25 08:00 PM ET
What is the market capitalization of Lineage Cell Therapeutics, Inc. Common Stock?
The market capitalization of Lineage Cell Therapeutics, Inc. Common Stock is 209.98M
How many shares of Lineage Cell Therapeutics, Inc. Common Stock are outstanding?
Lineage Cell Therapeutics, Inc. Common Stock has 210M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.